Position in GRFS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$298,365
+$35,975 QoQ
Shares Held
42,142
+28.8% QoQ
Ownership
0.006%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#68
of 164 holders
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026&PARTNERS holds $840,453,680 across 15 Drug Manufacturers - General names. GRFS ranks #15 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
180,745 | $216,790,993 | |
| 2 | JNJ |
Johnson & Johnson
|
809,873 | $205,683,445 | |
| 3 | ABBV |
AbbVie Inc.
|
425,683 | $107,118,870 | |
| 4 | AMGN |
Amgen Inc
|
280,838 | $101,697,056 | |
| 5 | MRK |
Merck & Co., Inc.
|
562,388 | $72,266,858 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
403,145 | $50,933,339 | |
| 7 | NVS |
Novartis AG
|
147,424 | $23,104,289 | |
| 8 | AZN |
Astrazeneca PLC
|
99,983 | $18,958,776 |
All Filings in GRFS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $298,365 | 42,142 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $262,390 | 32,717 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $210,234 | 22,485 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $357,424 | 35,886 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $148,870 | 16,468 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $146,487 | 20,603 | Shares | Sole | 2025-05-15 | |
| 2024-09-30 | $437,455 | 49,263 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||